COMMUNITY ACQUIRED PNEUMONIA (CAP)
Clinical trials for COMMUNITY ACQUIRED PNEUMONIA (CAP) explained in plain language.
Never miss a new study
Get alerted when new COMMUNITY ACQUIRED PNEUMONIA (CAP) trials appear
Sign up with your email to follow new studies for COMMUNITY ACQUIRED PNEUMONIA (CAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to calm immune overreaction in pneumonia patients with sepsis
Disease control Not yet recruitingThis early-stage study tests a new drug, OPT101, in 26 adults hospitalized with community-acquired pneumonia and sepsis. The goal is to check if the drug is safe and how the body processes it. Participants receive either OPT101 or a placebo for up to 4 days, and researchers monit…
Matched conditions: COMMUNITY ACQUIRED PNEUMONIA (CAP)
Phase: PHASE1 • Sponsor: Op-T LLC • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New DNA test aims to crack tough pneumonia cases
Diagnosis Not yet recruitingThis study tests whether a precise genetic test (tNGS) can help doctors treat hospitalized adults with pneumonia that isn't responding to initial antibiotics. About 524 participants will be randomly assigned to receive either standard care or the genetic test to identify the exac…
Matched conditions: COMMUNITY ACQUIRED PNEUMONIA (CAP)
Phase: NA • Sponsor: Capital Medical University • Aim: Diagnosis
Last updated May 15, 2026 11:56 UTC
-
Could less be more? new study tests lower antibiotic dose for pneumonia
Symptom relief Not yet recruitingThis study looks at whether a lower dose (1 gram daily) of the antibiotic ceftriaxone works as well as the standard higher dose (2 grams daily) for adults hospitalized with pneumonia but not in the ICU. The goal is to see if the lower dose leads to fewer side effects while still …
Matched conditions: COMMUNITY ACQUIRED PNEUMONIA (CAP)
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated May 17, 2026 03:10 UTC